MA27434A1 - DERIVES DE 6,7-DIHYDRO-5H-PYRAZOLO [1,2-a] PYRAZOL-1-ONES CONTROLANT LES CYTOKINES INFLAMMATOIRES - Google Patents

DERIVES DE 6,7-DIHYDRO-5H-PYRAZOLO [1,2-a] PYRAZOL-1-ONES CONTROLANT LES CYTOKINES INFLAMMATOIRES

Info

Publication number
MA27434A1
MA27434A1 MA28145A MA28145A MA27434A1 MA 27434 A1 MA27434 A1 MA 27434A1 MA 28145 A MA28145 A MA 28145A MA 28145 A MA28145 A MA 28145A MA 27434 A1 MA27434 A1 MA 27434A1
Authority
MA
Morocco
Prior art keywords
inflammatory cytokines
pyrazolo
pyrazol
dihydro
controlling inflammatory
Prior art date
Application number
MA28145A
Other languages
English (en)
Inventor
Michael Phillip Clark
Matthew John Laufersweiler
Adam Golebiowski
Mark P Sabat
Todd Andrew Brugel
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA27434A1 publication Critical patent/MA27434A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention répond aux besoins précités en ce que l'on a découvert, de manière surprenante, que certaines pyrazolones bicycliques et leurs dérivés sont efficaces pour inhiber la libération de cytokines inflammatoires, notamment, l'interleukine-1 (IL-1 ) et le facteur de nécrose tumorale (TNF) de cellules et, de ce fait, pour empêcher, diminuer ou autrement contrôler les enzymes qui sont censées être les composants actifs responsables des états pathologiques décrits dans la présente demande.
MA28145A 2002-09-18 2005-03-15 DERIVES DE 6,7-DIHYDRO-5H-PYRAZOLO [1,2-a] PYRAZOL-1-ONES CONTROLANT LES CYTOKINES INFLAMMATOIRES MA27434A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/246,214 US6730668B2 (en) 2001-09-20 2002-09-18 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Publications (1)

Publication Number Publication Date
MA27434A1 true MA27434A1 (fr) 2005-07-01

Family

ID=32028948

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28145A MA27434A1 (fr) 2002-09-18 2005-03-15 DERIVES DE 6,7-DIHYDRO-5H-PYRAZOLO [1,2-a] PYRAZOL-1-ONES CONTROLANT LES CYTOKINES INFLAMMATOIRES

Country Status (20)

Country Link
US (3) US6730668B2 (fr)
EP (1) EP1539761B1 (fr)
JP (1) JP2006502189A (fr)
KR (3) KR20050057444A (fr)
CN (1) CN1315834C (fr)
AT (1) ATE429434T1 (fr)
AU (1) AU2003218280B8 (fr)
BR (1) BR0314292A (fr)
CA (1) CA2496500A1 (fr)
DE (1) DE60327328D1 (fr)
ES (1) ES2322046T3 (fr)
IL (1) IL166822A0 (fr)
MA (1) MA27434A1 (fr)
MX (1) MXPA05002984A (fr)
NO (1) NO20051686L (fr)
NZ (1) NZ538197A (fr)
PL (1) PL376086A1 (fr)
RU (1) RU2289584C2 (fr)
WO (1) WO2004026878A1 (fr)
ZA (1) ZA200501590B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849627B2 (en) * 2001-09-20 2005-02-01 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6566357B1 (en) * 2001-09-20 2003-05-20 The Procter & Gamble Co. Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7326714B2 (en) * 2001-09-20 2008-02-05 The Procter & Gamble Company 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US7482356B2 (en) * 2003-11-10 2009-01-27 The Procter & Gamble Company Bicyclic pyrazolone cytokine inhibitors
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
RU2011151603A (ru) * 2009-05-19 2013-06-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭсСи Соединения и способы борьбы с грибами
US10512628B2 (en) 2016-04-24 2019-12-24 Solano S.P. Ltd. Dinotefuran liquid flea and tick treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124982A (en) 1965-02-09 1968-08-21 Lepetit Spa Diazabicyclo octanes and derivatives thereof
CH529153A (fr) 1969-10-27 1972-10-15 Lepetit Spa Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones
US6472416B1 (en) * 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
DE10004157A1 (de) * 2000-02-01 2001-08-02 Merckle Gmbh Chem Pharm Fabrik 4-Pyridyl-und 2,4-Pyrimidinyl-substituierte Pyrrolderivate und ihre Anwendung in der Pharmazie
US6566357B1 (en) * 2001-09-20 2003-05-20 The Procter & Gamble Co. Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Also Published As

Publication number Publication date
AU2003218280A1 (en) 2004-04-08
KR100842191B1 (ko) 2008-06-30
PL376086A1 (en) 2005-12-12
KR20070087684A (ko) 2007-08-28
CN1681819A (zh) 2005-10-12
RU2005111220A (ru) 2006-02-27
KR20070051374A (ko) 2007-05-17
US20040058944A1 (en) 2004-03-25
US7368455B2 (en) 2008-05-06
BR0314292A (pt) 2005-12-13
JP2006502189A (ja) 2006-01-19
DE60327328D1 (de) 2009-06-04
ZA200501590B (en) 2006-02-22
NZ538197A (en) 2007-01-26
ES2322046T3 (es) 2009-06-16
US6960593B2 (en) 2005-11-01
AU2003218280B2 (en) 2008-05-15
EP1539761B1 (fr) 2009-04-22
RU2289584C2 (ru) 2006-12-20
CN1315834C (zh) 2007-05-16
IL166822A0 (en) 2006-01-15
MXPA05002984A (es) 2005-06-22
ATE429434T1 (de) 2009-05-15
WO2004026878A1 (fr) 2004-04-01
CA2496500A1 (fr) 2004-04-01
EP1539761A1 (fr) 2005-06-15
KR20050057444A (ko) 2005-06-16
US6730668B2 (en) 2004-05-04
US20030134867A1 (en) 2003-07-17
AU2003218280B8 (en) 2008-06-26
US20050282844A1 (en) 2005-12-22
NO20051686L (no) 2005-04-05

Similar Documents

Publication Publication Date Title
MA27434A1 (fr) DERIVES DE 6,7-DIHYDRO-5H-PYRAZOLO [1,2-a] PYRAZOL-1-ONES CONTROLANT LES CYTOKINES INFLAMMATOIRES
EP1485381B8 (fr) Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2003038043A3 (fr) Combinaisons d'anticorps selectifs pour recepteur de ligand induisant l'apoptose liee au facteur de necrose tumorale et autres agents therapeutiques
IS2882B (is) Samsetning epóþílonhliðstæðna og virkra efna til efnameðferðar til þess að meðhöndla frumufjölgunarsjúkdóma
WO2007130383A3 (fr) Compositions et traitements utilisant des pyridazines et des secrétases
EP1712239A3 (fr) Inhibiteurs d'interleukine 1 dans le traitement de maladies
WO2003079973A3 (fr) Inhibiteurs de kinesine mitotique
WO2002085299A3 (fr) Traitements therapeutiques recourant a l'application directe de compositions metalliques antimicrobiennes
WO2004037171A3 (fr) Inhibiteurs de kinesine mitotiques
AU2003204620A1 (en) Adjustment of Ventilator Pressure-Time Profile to Balance Comfort and Effectiveness
WO2005056547A3 (fr) Quinoxalines utiles comme inhibiteurs des proteines kinases
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
AU2002352726A1 (en) Formulations and methods for treatment or amelioration of inflammatory conditions
WO2006030438A3 (fr) Utilisation de composes a base de tellure pour inhiber l'enzyme de conversion de l'interleukine
WO2005037836A3 (fr) Imidazopyrazines utilisees comme inhibiteurs de la tyrosine kinase
WO2004046120A3 (fr) Diaminotriazoles convenant comme inhibiteurs de proteine kinases
EP2050750A3 (fr) Composés multi-cycliques et leur utilisation comme inhibiteurs des enzymes PARP, VEGFR2 et MLK3
WO2005017190A3 (fr) Inhibiteurs de kinesine mitotique
WO2004100987A3 (fr) Procede d'utilisation d'antagonistes de l'il1 pour le traitement d'hyperplasie neointimale
WO2005077344A3 (fr) Inhibiteurs de la necrose cellulaire
WO2005018547A3 (fr) Inhibiteurs de kinesine mitotique